<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Madden PJ</submitter><funding>Howard Hughes Medical Institute</funding><funding>NIAID NIH HHS</funding><funding>NIH HHS</funding><pagination>997-1014.e11</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12060733</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>58(4)</volume><pubmed_abstract>Rare naive B cells have special pathogen-recognition features that enable outsized contributions to protective immunity but infrequently participate in immune responses. We investigatee how germline-targeting vaccine delivery and adjuvant selection affect priming of exceptionally rare BG18-like HIV broadly neutralizing antibody-precursor B cells (&lt;1-in-50 million) in non-human primates. Only escalating dose (ED) priming immunization using the saponin adjuvant SMNP elicited detectable BG18-like cells in germinal centers (GCs) compared with other conditions. All groups had strong GC responses, but only ED+SMNP and bolus+SMNP induced BG18-like memory B cells in >50% of animals. One group had vaccine-specific GC responses equivalent to ED+SMNP but scarce BG18-like B cells. Following homologous</pubmed_abstract><journal>Immunity</journal><pubmed_title>Diverse priming outcomes under conditions of very rare precursor B cells.</pubmed_title><pmcid>PMC12060733</pmcid><funding_grant_id>R37 AI125068</funding_grant_id><funding_grant_id>S10 OD025052</funding_grant_id><funding_grant_id>UM1 AI144462</funding_grant_id><funding_grant_id>P51 OD011132</funding_grant_id><funding_grant_id>S10 OD026799</funding_grant_id><pubmed_authors>Marina-Zarate E</pubmed_authors><pubmed_authors>Irvine DJ</pubmed_authors><pubmed_authors>Schultze S</pubmed_authors><pubmed_authors>Georgeson E</pubmed_authors><pubmed_authors>Shil M</pubmed_authors><pubmed_authors>Maiorino L</pubmed_authors><pubmed_authors>Lewis VR</pubmed_authors><pubmed_authors>Zhou A</pubmed_authors><pubmed_authors>Crotty S</pubmed_authors><pubmed_authors>Phelps N</pubmed_authors><pubmed_authors>Alavi N</pubmed_authors><pubmed_authors>Liguori A</pubmed_authors><pubmed_authors>Steichen JM</pubmed_authors><pubmed_authors>Rodrigues KA</pubmed_authors><pubmed_authors>Schief WR</pubmed_authors><pubmed_authors>Pradhan A</pubmed_authors><pubmed_authors>Pai Kasturi S</pubmed_authors><pubmed_authors>Madden PJ</pubmed_authors><pubmed_authors>Michaels KK</pubmed_authors><pubmed_authors>Ni K</pubmed_authors><pubmed_authors>Melo MB</pubmed_authors><pubmed_authors>Lopez PG</pubmed_authors><pubmed_authors>Shields K</pubmed_authors><pubmed_authors>Lu D</pubmed_authors><pubmed_authors>Flynn C</pubmed_authors><pubmed_authors>Lemnios A</pubmed_authors><pubmed_authors>Xiao S</pubmed_authors><pubmed_authors>Kubitz M</pubmed_authors><pubmed_authors>Phung I</pubmed_authors><pubmed_authors>Bosinger SE</pubmed_authors><pubmed_authors>Saha S</pubmed_authors><pubmed_authors>Carnathan DG</pubmed_authors><pubmed_authors>Smith ML</pubmed_authors><pubmed_authors>Lim D</pubmed_authors><pubmed_authors>Metz A</pubmed_authors><pubmed_authors>Eskandarzadeh S</pubmed_authors><pubmed_authors>Gregory J</pubmed_authors><pubmed_authors>Rodriguez OL</pubmed_authors><pubmed_authors>Healy BS</pubmed_authors><pubmed_authors>Ben-Akiva E</pubmed_authors><pubmed_authors>Pinney W</pubmed_authors><pubmed_authors>Watson CT</pubmed_authors><pubmed_authors>Upadhyay AA</pubmed_authors><pubmed_authors>Silvestri G</pubmed_authors><pubmed_authors>Kalyuzhiny O</pubmed_authors></additional><is_claimable>false</is_claimable><name>Diverse priming outcomes under conditions of very rare precursor B cells.</name><description>Rare naive B cells have special pathogen-recognition features that enable outsized contributions to protective immunity but infrequently participate in immune responses. We investigatee how germline-targeting vaccine delivery and adjuvant selection affect priming of exceptionally rare BG18-like HIV broadly neutralizing antibody-precursor B cells (&lt;1-in-50 million) in non-human primates. Only escalating dose (ED) priming immunization using the saponin adjuvant SMNP elicited detectable BG18-like cells in germinal centers (GCs) compared with other conditions. All groups had strong GC responses, but only ED+SMNP and bolus+SMNP induced BG18-like memory B cells in >50% of animals. One group had vaccine-specific GC responses equivalent to ED+SMNP but scarce BG18-like B cells. Following homologous</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Apr</publication><modification>2026-06-02T13:09:49.505Z</modification><creation>2026-04-18T03:11:23.191Z</creation></dates><accession>S-EPMC12060733</accession><cross_references><pubmed>40168992</pubmed><doi>10.1016/j.immuni.2025.03.003</doi></cross_references></HashMap>